R. Ghalib
About
R. Ghalib is a scholar working on Hepatology, Epidemiology and Immunology.
According to data from OpenAlex, R. Ghalib has authored 26 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 14 papers in Epidemiology and 9 papers in Immunology. Recurrent topics in R. Ghalib's work include Hepatitis C virus research (13 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). R. Ghalib is often cited by papers focused on Hepatitis C virus research (13 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). R. Ghalib collaborates with scholars based in United States, Germany and Italy. R. Ghalib's co-authors include Eric Lawitz, Mark Sulkowski, Megan Wind‐Rotolo, Dennis M. Grasela, David Gardiner, Fiona McPhee, M. J. Selby, Vikram Kansra, Israel Lowy and Jeffrey Anderson and has published in prestigious journals such as Gastroenterology, PLoS ONE and Journal of Hepatology.
In The Last Decade
R. Ghalib
25 papers receiving 549 citations
Peers
R. Ghalib
Sayuri Nitta Japan
Vincent Leroy France
Sun Suk Kim South Korea
Dao-zhen Xu China
Frank Krux Germany
Antonio Madejón Spain
Jeroen van de Wetering de Rooij United States
Gidon Ellis United Kingdom
Fareed Rahman Germany
Koichi Kanai Japan
Citations per year, relative to R. Ghalib R. Ghalib (= 1×)
peers
Sayuri Nitta
Countries citing papers authored by R. Ghalib
Since
Specialization
Citations
This map shows the geographic impact of R. Ghalib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Ghalib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Ghalib more than expected).
Fields of papers citing papers by R. Ghalib
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by R. Ghalib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Ghalib. The network helps show where R. Ghalib may publish in the future.
Co-authorship network of co-authors of R. Ghalib
This figure shows the co-authorship network connecting the top 25 collaborators of R. Ghalib. A scholar is included among the top collaborators of R. Ghalib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Ghalib. R. Ghalib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Forns, Xavier, Joaquin Valdes, Sabela Lens, et al.. (2017). EXPEDITION-I: efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis. Journal of Hepatology. 66(1). S3–S4.
2.
Zeuzem, Stefan, R. Ghalib, Paul J. Pockros, et al.. (2015). G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection. Journal of Hepatology. 62. S213–S213.
3.
Läwitz, E., Christophe Hézode, Edward Gane, et al.. (2014). O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY. Journal of Hepatology. 60(1). S25–S26.
4.
Sulkowski, Mark, Ira M. Jacobson, R. Ghalib, et al.. (2014). O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS. Journal of Hepatology. 60(1). S4–S4.
5.
Gardiner, David, Jay Lalezari, Eric Lawitz, et al.. (2013). A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE. 8(5). e63818–e63818.
6.
Thompson, A., Lorenzo Rossaro, R. Ghalib, et al.. (2013). 64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS. Journal of Hepatology. 58. S29–S29.
7.
Tatum, H., Paul J. Thuluvath, E. Läwitz, et al.. (2012). 1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION. Journal of Hepatology. 56. S460–S460.
8.
Rodríguez‐Torres, M., E. Läwitz, Barbara R. Conway, et al.. (2010). 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS. Journal of Hepatology. 52. S14–S14.
9.
Ghalib, R., et al.. (2010). 32 A PHASE 1, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-ESCALATION STUDY OF IMO-2125, A TLR9 AGONIST, IN HEPATITIS C-NONRESPONDERS. Journal of Hepatology. 52. S14–S14.
10.
Gordon, Fredric D., Paul Y. Kwo, R. Ghalib, et al.. (2010). 23 PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR HEPATITIS C RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANTATION (OLT): FINAL RESULTS FROM THE PROTECT STUDY. Journal of Hepatology. 52. S10–S11.
11.
Sulkowski, Mark, Stephen A. Harrison, Lorenzo Rossaro, et al.. (2010). Impaired Fasting Glucose Is Associated With Lower Rates of Sustained Virologic Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC): Retrospective Analysis of the IDEAL Study.
12.
Pol, S., Greg Everson, R. Ghalib, et al.. (2010). 1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL. Journal of Hepatology. 52. S462–S462.
13.
Long, W.A., К. Tchernev, Iskren Kotzev, et al.. (2010). 2010 Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B + RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B + RIBAVIRIN IN TREATMENT-NAIVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS. Journal of Hepatology. 52. S467–S467.
14.
Läwitz, E., Curtis Cooper, M. Rodríguez‐Torres, et al.. (2009). 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION. Journal of Hepatology. 50. S37–S37.
15.
Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371.
16.
Nelson, Daniel, Paul J. Pockros, Eliot Godofsky, et al.. (2008). 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN. Journal of Hepatology. 48. S371–S371.
17.
Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246.
18.
Lowell, Jeffrey A., Silvia Taranto, Gad Singer, et al.. (1997). Transplant recipients as organ donors: The domino transplant. Transplantation Proceedings. 29(8). 3392–3393.
19.
Lowell, Jeffrey A., Surendra Shenoy, R. Ghalib, et al.. (1997). Liver transplantation after jejunoileal bypass for morbid obesity. Journal of the American College of Surgeons. 185(2). 123–127.
20.
Ghalib, R., Gary R. Zuckerman, Jeffrey A. Lowell, et al.. (1995). The value of routine lower GI studies for patients undergoing liver transplantation evaluation. Gastroenterology. 108(4). A1071–A1071.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sayuri Nitta Breakdown of academic impact, for papers by Vincent Leroy Breakdown of academic impact, for papers by Sun Suk Kim Breakdown of academic impact, for papers by Dao-zhen Xu Breakdown of academic impact, for papers by Frank Krux Breakdown of academic impact, for papers by Antonio Madejón Breakdown of academic impact, for papers by Jeroen van de Wetering de Rooij Breakdown of academic impact, for papers by Gidon Ellis Breakdown of academic impact, for papers by Fareed Rahman Breakdown of academic impact, for papers by Koichi Kanai